Checchi Capital Advisers LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 6.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,128 shares of the life sciences company’s stock after acquiring an additional 68 shares during the period. Checchi Capital Advisers LLC’s holdings in Illumina were worth $244,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tcwp LLC purchased a new position in Illumina in the first quarter worth $31,000. WASHINGTON TRUST Co purchased a new position in Illumina in the first quarter worth $35,000. Brown Brothers Harriman & Co. grew its position in Illumina by 460.9% in the first quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after acquiring an additional 106 shares in the last quarter. Benjamin Edwards Inc. lifted its stake in Illumina by 13,300.0% in the first quarter. Benjamin Edwards Inc. now owns 134 shares of the life sciences company’s stock worth $47,000 after purchasing an additional 133 shares during the last quarter. Finally, Glassman Wealth Services lifted its stake in Illumina by 72.9% in the second quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock worth $27,000 after purchasing an additional 62 shares during the last quarter. 86.12% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts have weighed in on ILMN shares. StockNews.com started coverage on shares of Illumina in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Cowen boosted their price target on shares of Illumina from $327.00 to $350.00 in a research note on Friday, November 4th. Robert W. Baird lowered their price target on shares of Illumina from $215.00 to $210.00 in a research note on Friday, November 4th. Credit Suisse Group lowered their price target on shares of Illumina from $230.00 to $225.00 and set a “neutral” rating for the company in a research note on Friday, November 4th. Finally, Barclays upped their price objective on shares of Illumina from $130.00 to $175.00 and gave the company an “underweight” rating in a research note on Friday, September 30th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average target price of $254.38.
Illumina Price Performance
Insider Buying and Selling
In other Illumina news, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $223.65, for a total value of $111,825.00. Following the sale, the senior vice president now owns 40,112 shares in the company, valued at $8,971,048.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by insiders.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.